UK company Exonate announced plans to initiate a phase 2b clinical trial to further evaluate the clinical efficacy, optimal dosing and safety profile of EXN407, a twice-daily eye drop, in patients wit
A survey found eyecare professionals (ECPs) use lifitegrast 5% (Xiidra, Bausch + Lomb) to treat one fifth of their patients with dry eye disease (DED) and reported moderate-to-high personal and patien
Jon Baines Tours, a specialist travel company curating professional and cultural study tours, is offering two ophthalmic tours in 2026, one traversing Nepal and Bhutan and another exploring historical
Auckland University's Prof Craig is the new chair of the international Tear Film & Ocular Surface Society
Cornea and anterior segment specialist Dr Bia Kim has joined the team at Auckland Eye. “We are pleased to welcome Dr Kim,” said Gordon Armstrong, Auckland Eye CEO. “Dr Kim brings a wealth of interna
The Government is establishing a primary care advisory group to support its primary care reform programme, health minister Simeon Brown has announced.
A two-year efficacy trial of the minimally invasive glaucoma surgery (MIGS) iStent Inject W device found it significantly reduced intraocular pressure (IOP) and glaucoma medication burden in adult Jap
A Taiwanese study has shown that patients with dry eye disease (DED) who’d previously had keratorefractive surgery (KRS) had more risk factors and thus poorer outcomes with intense pulsed light (IPL)
Bausch + Lomb (B+L) is changing distributor in New Zealand – its pharma portfolio is now with longtime surgical distributor Toomac Ophthalmic and the contact lens and solutions portfolio is transferring to Healthcare Logistics (HCL) from 1 September.
A first-in-human phase 2 clinical trial of ILYX-002, a topical immunomodulator for moderate-to-severe dry eye disease (DED) associated with systemic autoimmune or inflammatory conditions, demonstrated
Join Eye Health Aotearoa and the Parliamentary Friends of Eye Health for World Sight Day at Parliament!
